Richard A. Larson to Aminoglycosides
This is a "connection" page, showing publications Richard A. Larson has written about Aminoglycosides.
Connection Strength
1.214
-
Final report of the efficacy and safety of gemtuzumab ozogamicin (Mylotarg) in patients with CD33-positive acute myeloid leukemia in first recurrence. Cancer. 2005 Oct 01; 104(7):1442-52.
Score: 0.270
-
Antibody-targeted chemotherapy of older patients with acute myeloid leukemia in first relapse using Mylotarg (gemtuzumab ozogamicin). Leukemia. 2002 Sep; 16(9):1627-36.
Score: 0.218
-
Current use and future development of gemtuzumab ozogamicin. Semin Hematol. 2001 Jul; 38(3 Suppl 6):24-31.
Score: 0.201
-
New agents for induction and postremission therapy of acute myeloid leukemia. Leukemia. 2001 Apr; 15(4):675-6.
Score: 0.198
-
A phase 3 study of gemtuzumab ozogamicin during induction and postconsolidation therapy in younger patients with acute myeloid leukemia. Blood. 2013 Jun 13; 121(24):4854-60.
Score: 0.114
-
Gemtuzumab ozogamicin: time to resurrect? J Clin Oncol. 2012 Nov 10; 30(32):3921-3.
Score: 0.109
-
Efficacy and safety of gemtuzumab ozogamicin in patients with CD33-positive acute myeloid leukemia in first relapse. J Clin Oncol. 2001 Jul 01; 19(13):3244-54.
Score: 0.050
-
Arsenic trioxide during consolidation for patients with previously untreated low/intermediate risk acute promyelocytic leukaemia may eliminate the need for maintenance therapy. Br J Haematol. 2014 May; 165(4):497-503.
Score: 0.030
-
High dose cytarabine plus gemtuzumab ozogamicin for patients with relapsed or refractory acute myeloid leukemia: Cancer and Leukemia Group B study 19902. Leuk Res. 2011 Mar; 35(3):329-33.
Score: 0.024